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Distinguishing remnant ablation from adjuvant treatment in differentiated thyroid cancer
Following thyroidectomy, radioactive iodine (¹³¹I) therapy can be given in an effort to destroy residual, presumably benign thyroid tissue in the thyroid bed (remnant ablation), suspected but not identified remaining disease (adjuvant treatment), or known residual or recurrent disease (treatment of known disease). 1, 2 Unlike treatment of known disease, adjuvant ¹³¹I therapy is given for a risk and not for documented persistent disease. For remnant ablation, success is defined as having no biochemical, functional, or structural evidence of persistent thyroid cells 6-12 months after ¹³¹I ablation. Conversely, the success of adjuvant therapy is defined by improvements in disease-specific survival and structural disease recurrence rates, whereas destruction (and possibly stabilisation) of known disease would be considered an important measure of success for treatment of known disease.
Results of two randomised non-inferiority trials, HiLo and ESTIMABL1, have shown that preparation with either thyroid hormone withdrawal or recombinant human thyroid-stimulating hormone (rhTSH), with administered activities of 1·1 GBq or 3·7 GBq, can achieve successful remnant ablation in 85-95% of patients. 3, 4 In The Lancet Diabetes & Endocrinology, Hakim-Moulay Dehbi and colleagues 5 now report longterm results of the HiLo trial. To assess the effect of the first administered activity of ¹³¹I for adjuvant treatment or treatment of known disease, they report the rates of persistent disease (biochemical or structural evidence of disease remaining after initial therapy) or recurrent disease (biochemical or structural disease subsequently identified in patients deemed to be disease free following initial therapy) detected over a median of 6·5 years of follow-up. 5 Recurrence rates based on a median follow-up of 5·4 years have recently also been reported for ESTIMABL1. 6 Results of both trials confirm previous retrospective observations showing structural disease persistence and recurrence rates of less than 5% in patients with low to intermediate risk differentiated thyroid cancer. 5, 6 They also show the importance of modifying risk estimates in response to initial therapy, as the rate of recurrent and persistent structural disease in patients who achieved successful remnant ablation dropped to less than 1%, whereas 15% of patients who did not achieve initial ablation were diagnosed with persistent or recurrent disease. 5, 6 In the HiLo trial, recurrent or persistent structural disease was detected much earlier in patients who did not have successful ablation compared with patients who had successful ablation (data in appendix 5 ). Thus, the success or failure of remnant ablation, assessed as early as 6-9 months after initial therapy, should be used to modify the frequency and intensity of follow-up that is planned on the basis of initial American Thyroid Association (ATA) risk stratification.
However, it is important to remember that both of these trials were primarily designed and powered to assess the efficacy of remnant ablation in low to intermediate risk patients. 3, 4 As a result, these trials cannot provide definitive answers about the need for, or efficacy of, ¹³¹I therapy given primarily for adjuvant treatment. The low event rates (disease-specific mortality <1% and structural disease recurrence rates of <10%) anticipated in a properly designed adjuvant therapy trial of low to intermediate risk patients will require much larger samples sizes and longer follow-up periods. 7 Furthermore, since properly selected low to intermediate risk patients treated with thyroid surgery alone also have low structural disease recurrence rates, it is important to include a control group followed up without ¹³¹I adjuvant therapy in order to ascertain whether the excellent outcomes following initial therapy are a reflection of the effect of thyroid surgery coupled with the indolent nature of differentiated thyroid cancer or whether ¹³¹I therapy is having a meaningful impact on disease recurrence and overall survival.
The authors of both the HiLo and ESTIMABL1 trials are to be commended on the design, implementation, and publication of these multicentre, randomised prospective trials that have provided reliable evidence about preparation methods and appropriate admin istered activities of ¹³¹I for remnant ablation. We look forward to the results of their currently accruing trials, the IoN trial (NCT01398085) and ESTIMABL2 (NCT01837745), examining the rates of persistent and recurrent disease in patients randomly assigned to either low-dose ¹³¹I or observation following total thyroidectomy. 8 These successful trials should provide the impetus for the thyroid cancer community to design and implement prospective, randomised clinical trials specifically designed to assess the efficacy and optimal administered activity of ¹³¹I when used as adjuvant treatment. To that end, selection of patients for adjuvant treatment trials should be based not only on initial risk stratification (eligibility based on estimates of the risk of recurrence or disease-specific mortality) but also on careful evaluation of disease status following appropriate initial surgery so that we can differentiate the potential role of ¹³¹I therapy for the treatment of known persistent disease from that of true adjuvant treatment.
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